

DEA CAPITAL

BUY

. .

Target Price (Eu):

Price (Eu):

1.51

2.00

SECTOR: Holdings & RE

Micaela Ferruta +39-02-77115.428

e-mail: ferruta@intermonte.it

Incorporating the Value of the Migros Deal

- NAV rises from Eu2.60 per share to Eu2.75 per share at the end of March, mainly related to a revaluation of the stake in Kenan (Migros) from Eu195mn to Eu235mn, assuming a value of TRY18ps (or 13x EBITDA) for Migros (still considerably lower than the TRY25/share placement price and the TRY22/share market price as at 16th May). DeA Capital's net debt as at 31/3/2011 stood at Eu24.9mn prior to the Eu50mn dividend from Kenan (arriving in 2Q). The company booked a consolidated loss of Eu6.6mn in 1Q11, vs. a Eu6.8mn loss expected, although a Eu44mn net profit would be posted under IAS1, including a Eu42mn increase in the fair value of Kenan.
- Kenan, which owned 98.4% of Migros, sold a 17.4% stake for TRY 25 per share on 17th April, for a total of TRY 775mn (around Eu350mn). Migros currently trades at TRY xx. The amount pertaining to DeA Capitalf from the disposal is Eu58mn, of which Eu50mn was cashed in on 5th May. The Migros market float has been restored to around 19.5% through this placement, while DeA Capital's indirect stake has been reduced to 13.7%.
- Migros Turk (29% of pro-forma NAV and 29% of our valuation) reported TRY 1.57bn in revenues for the year (+10% YoY); the gross margin rose 9% YoY, but EBITDA fell by 6.2% YoY due to the costs connected with repositioning the stores under the \$ok brand into a hard discount. These higher costs will probably be present in 2Q11 as well; as such, we have reduced our FY11 estimates, but have left our 2012-13 forecast unchanged.
- Other Operating companies reported results that were in line with estimates. We therefore substantially confirm our 2011 estimates on Générale de Santé, as well as on IDEA AI and also, for the time being, on F.A.R.E. standalone, as we await more details on the F.A.R.E.- Fimit merger. We would expect a business plan for the combined entity to be presented after the summer, leading to the creation of the largest independent real estate asset manager in Italy which will have around Eu8bn in AuM and 19 managed funds.
- We confirm our positive view on DeA Capital, raising the target price from Eu1.70 to Eu2.00. We are incorporating the value of the Migros placement and a valuation of the remaining 13.7% stake in Migros at market value (TRY 22 p.s.). This leads to an increase of our NAV by Eu0.3/share to Eu2.00, confirming our positive view. We would still expect DeA to exit this indirect investment in 2011-12 and believe that the first placement sets a ballpark price tag on the total value of Migros. On top of this, we see an exit from the GDS stake as a medium term goal, while alternative asset management is now considered core. In fact, the FARE-FIMIT merger will increase focus on AAM and the 3Y plan set to be released after the summer could be the focus of newsflow in 2H11. At current prices, DeA Capital is trading at a 43% discount to the total value of its investments, which is Eu2.75 per share. If we were to strip out the valuation of Kenan (Migros) and Santé (GDS) from current market prices, the implied value of AAM activities would be close to zero.

| Key Figures | 2009A | 2010A | 2011E | 2012E | 2013E |
|--------------------|-------|-------|-------|-------|-------|
| EBIT (Eu mn) | (1) | (2) | 1 | 8 | 13 |
| Net profit (Eu mn) | -29 | -26 | 13 | 3 | 12 |
| EPS - New (Eu) | -0.01 | -0.04 | -0.04 | 0.01 | 0.04 |
| EPS - Old (Eu) | -0.01 | -0.04 | -0.03 | 0.00 | 0.03 |
| DPS (Eu) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| NAVPS (Eu) | 2.66 | 2.49 | 2.67 | 2.68 | 2.72 |
| Ratios & Multiples | 2009A | 2010A | 2011E | 2012F | 2013F |

| Ratios & Multiples | 2009A | 2010A | 2011E | 2012E | 2013E |
|--------------------|-------|-------|-------|-------|-------|
| P/E | nm | nm | nm | nm | 37.1 |
| Div. Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| P/NAVPS | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
| ROCE | | | | | |

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and of any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization.

DEA CAPITAL - 12m Performance



| RATING: Unchanged | | |
|-------------------------|-----------|-------|
| TARGET PRICE (Eu): from | n 1.70 to | 2.00 |
| Change in EPS est: | 2011E | 2012E |
| | 37.4% | n.m. |

STOCK DATA

Reuters code:

| Bloomberg code | e: | | DEA IM |
|----------------|-------|-------|---------|
| Performance | 1m | 3m | 12m |
| Absolute | -5.7% | 9.1% | 26.0% |
| Relative | -5.1% | 13.0% | 17.0% |
| 12 months H/L: | | 1. | 60/1.12 |

DEA.MI

| SHAREHOLDER DATA | |
|---------------------------|-------|
| No. of Ord. shares (mn): | 307 |
| Total No. of shares (mn): | 307 |
| Mkt Cap Ord (Eu mn): | 462 |
| Total Mkt Cap (Eu mn): | 462 |
| Mkt Float - ord (Eu mn): | 156 |
| Mkt Float (in %): | 33.7% |
| Main shareholder: | |
| De Agostini | 58.3% |
| BALANCE SHEET DATA | 2011 |
| Book value (Eu mn): | 820 |
| BVPS (Eu): | 2.67 |
| P/BV: | 0.6 |
| Net Debt (Eu mn): | -15 |
| NAV (Eu mn) | 820 |



| CAPITAL - KEY FIGURES | | 2009A | 2010A | 2011E | 2012E | 2013 |
|-----------------------|--|------------|------------|------------|------------|-----------|
| | Fiscal year end | 31/12/2009 | 31/12/2010 | 31/12/2011 | 31/12/2012 | 31/12/201 |
| PROFIT & LOSS (Eu mn) | Sales | 34 | 38 | 50 | 55 | 6 |
| | EBITDA | (1) | (2) | 1 | 8 | 1 |
| | EBIT | (1) | (2) | 1 | 8 | 1 |
| | Financial income (charges) | (4) | (5) | (1) | (O) | |
| | Associates & Others | (28) | (16) | (6) | 4 | |
| | Pre-tax profit (loss) | (32) | (22) | 19 | 11 | 2 |
| | Taxes | 3 | (3) | (5) | (7) | (7 |
| | Tax rate (%) | 9.6% | -15.6% | 24.2% | 58.0% | 32.5 |
| | Minorities & discontinue activities | (O) | (1) | (1) | (2) | (3 |
| | Net profit | -29 | -26 | 13 | 3 |] |
| | Total extraordinary items | (1) | (0) | | | |
| | Ebitda excl. extraordinary items | (1) | (2) | 1 | 8 | 1 |
| | Ebit excl. extraordinary items | (0) | (1.1) | (11) | 0 | , |
| | Net profit restated | (2) | (11) | (11) | 3 | 1 |
| PER SHARE DATA (Eu) | Total shares out (mn) - average fd | 307 | 307 | 307 | 307 | 30 |
| | EPS stated fd | -0.10 | -0.09 | 0.04 | 0.01 | 0.0 |
| | EPS restated fd | -0.01 | -0.04 | -0.04 | 0.01 | 0.0 |
| | BVPS fd | 2.54 | 2.49 | 2.67 | 2.68 | 2.7 |
| | NAVPS fd | 2.66 | 2.49 | 2.67 | 2.68 | 2 |
| | Dividend per share (ord) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 |
| | Dividend pay out ratio (%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0 |
| CASH FLOW (Eu mn) | Change in NWC | 0 | 0 | 0 | 0 | |
| | Capital expenditure | 0 | 0 | 0 | 0 | |
| | Other cash items | 0 | 0 | 0 | 0 | |
| | Free cash flow (FCF) | 0 | 0 | | 0 | |
| | Acquisitions, divestments & other | | | | | |
| | Dividend Change in Not Financial Position | (50) | 15 | 36 | 1 | 4 |
| | Change in Net Financial Position | (52) | | | | |
| BALANCE SHEET (Eu mn) | Total fixed assets | 812 | 784 | 803 | 804 | 79 |
| | Net working capital | 3 | 1 | 1 | 1 | |
| | Long term liabilities | 015 | 705 | 00.4 | 00.4 | 7/ |
| | Net capital employed | 815 | 785 | 804 | 806 | 79 |
| | Net financial position | 35 | 20 | (15) | (17) | (4 |
| | Group equity | 780 | 765 | 820 | 822 | 8 |
| | Minorities | 0 | 0 | 0 | 0 | 0 |
| | Net equity | 780 | 765 | 820 | 822 | 8: |
| NAV DATA (Eu mn) | Properties and other assets - Book value | | | | | |
| | Properties and other assets - Market value | 015 | 7.5 | 000 | 000 | 0.1 |
| | NAV | 815 | 765 | 820 | 822 | 83 |
| RATIOS(%) | EBITDA margin* | nm | nm | 2.3% | 14.7% | 21.5 |
| | EBIT margin* | | | | | |
| | Gearing - Debt/equity | -4.5% | -2.7% | 1.9% | 2.0% | 5.3 |
| | Interest cover on EBIT | nm | nm | 1.4 | 24.5 | n |
| | Debt/Ebitda | 48.07 | 10.82 | 13.63 | 2.05 | 3.4 |
| | Capex as % sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0 |
| | ROCE* | | | | | |
| | ROE* | 000.407 | 11.007 | 20.497 | 11.007 | 0.0 |
| GROWTH RATES (%) | Sales | 293.4% | 11.8% | 30.4% | 11.8% | 8.5 |
| | EBITDA* | nm | nm | nm | 617.9% | 58.6 |
| | EBIT* | | | | 70.10 | 0540 |
| | Net profit | nm | nm | nm | -79.1% | 354.3 |
| | EPS restated | nm | nm | nm | nm | 354.3 |

 $^{^{}st}$ Excluding extraordinary items

Source: Intermonte SIM estimates

NAV and Valuation

Kenan, owner of 97.9% of Migros, sold 17.4% of the Migros share capital for TRY25 per share on 17th April, for a total of TRY775mn (around Eu350mn). The amount pertaining to DeA Capital - which owns a 17% stake in the Kenan consortium - is Eu58mn, of which Eu50mn was cashed in on 5th May; in 2Q11 DeA Capital will book a Eu24mn capital gain from the transaction.

Since this placement, the Migros market float has been restored to around 19.5%, with Kenan remaining the controlling shareholder with a stake of around 80.5%; as a result DeA Capital's indirect stake in Migros went down to 13.7%. Although the Migros placement occurred in 2Q11, some of the impact was already reflected in 1Q11 figures, as explained below.

In 1Q11 the company booked a consolidated FY net loss of Eu6.6mn vs. Eu6.8mn expected. Breaking down the 1Q11 loss, the private equity division lost Eu5.6mn asset management delivered a profit of Eu1.2mn after PPA and there were Eu2.2mn in holding costs. The group posted a positive net result of Eu44mn according to IAS1, however, including a Eu42mn increase in the fair value of Kenan

| DEACAPITAL Group P&L (Eu m) | 1Q10 A | 2Q10 A | 3Q10 A | 9M10 | 4Q10 A | 2,010 | 1Q11 E | 1Q11 A | % diff |
|-------------------------------|-------------|-------------|---------|---------|--------|---------|----------|---------|--------|
| Private equity | 9.87 - | - 4.07 - | 9.90 - | 4.10 - | 18.30 | - 22.40 | - 6.62 - | 5.60 | -15% |
| Alternative AM | 0.68 | 1.02 | 3.2 | 4.00 | -0.12 | 4.80 | 1.8 | 1.2 | -33% |
| Holding COSTS/fin charges | - 2.83 - | - 3.17 - | 0.80 - | 6.80 - | 2.00 | - 8.80 | -2.0 | (2.20) | 10% |
| Net profit | 7.72 | - 6.22 - | 8.40 - | 6.90 - | 19.45 | - 26.35 | (6.83) | (6.60) | -3% |
| NFP | - 34.90 | - 29.70 - | 16.70 - | 16.70 - | 20.40 | - 20.40 | (27.23) | (24.90) | -9% |
| Equity | 789.60 | 789.60 | 824.00 | 861.20 | 764.00 | 764.00 | 823.24 | 805.80 | |
| p.s. (before BB) | 2.58 | 2.58 | 2.69 | 2.81 | 2.49 | 2.49 | 2.80 | 2.75 | |
| Source: Company Data and Inte | ermonte SIA | 1 estimates | | | | | • | | |

DeA Capital's NAV stood at Eu2.75ps as of March 2011 vs. Eu2.60 as at the end of 2010. The difference is mostly related to upward adjustments to the book value of Kenan (Migros), partially incorporating the capital gain achieved due to the placement of a 17% stake in Migros.

DeA Capital's stake in Migros is now valued at Eu235mn, vs. Eu195mn previously, or 13.4x EV/EBITDA. This still does not fully incorporate the value of the stake based on the TRY25 per share placement (Migros traded at TRY 22 as of yesterday).

| DeA Capital NAV at Pro- | | 30/03/2011 | | | | | | |
|-----------------------------|-----------------|------------|-----------------|-------------|----------|-------------------------------------|-----------------|------------------|
| Asset | Activity | Stake | Value (€ mn) | per share € | % of NAV | Valuation method | Value (€ mn) | vs. OLD Value |
| Santè SA | Healthcare | 42.9% | 286.1 | 0.98 | 35.5% | Net equity 9.1x 2010 Ebitda | 282.9 | 1.1% |
| Kenan (Migros) | Food Retailer | 17.1% | 237.0 | 0.81 | 29.4% | Fair value* 13x 2010 Ebitda | 195.0 | 21.5% |
| FARE (ATLANTIC) SGR*** | Alternative AM | 100.0% | 82.3 | 0.28 | 10.2% | Net equity/Fair Value 3.0% P/AUM | 89.9 | -8.5% |
| IDeA Alternative Inv. SGR | Alternative AM | 100.0% | 67.7 | 0.23 | 8.4% | Net equity 4.5% P/AUM | 61.0 | 11.0% |
| Sigla | Consumer Credit | 41.4% | 22.1 | 0.08 | 2.7% | Net equity | 22.1 | 0.0% |
| IDeA Funds (FOF & Colnv) | Private Equity | n.m. | 119.8 | 0.41 | 14.9% | Fair value* | 119.8 | 0.0% |
| Other Investments | | | 15.1 | | | | 29.5 | -49.0% |
| NFP and other | | | -24.3 | -0.08 | -3.0% | | -36.2 | n.m. |
| Total ex treasury Shares | | | 806 | 2.75 | 101.8% | | 764 | 5.5% |
| # shares (min) net of Buy E | Back | | | 293.0 | | | | |

^{***} including the exercise of 30% option

^{*} updated quarterly by fund managers

| 1.50 |
|------|
| -45% |
| -43% |
| |

Source: Intermonte SIM and Company Data





DEA CAPITAL NAV: Our Valuation Rises to Eu2.00

We are incorporating the value of the Migros placement and a valuation of the remaining 13.7% Migros stake at TRY22p.s. (market price as of 16/5/11), which increases our NAV to Eu2.00. We would still expect an exit from the indirect investment in Migros in 2011-12, and believe that the placement sets a price tag on the value of this investment.

We would like to highlight that over the next 2-3 years DeA Capital will probably seek an exit from private equity investments (Migros Turk and GDS), and the proceeds will be returned to shareholders and/or reinvested in alternative asset management (AAM) activities, which are seen as core. In fact, the FARE-FIMIT 3Y plan that is set to be released after the summer could be the focus of newsflow for the stock in 2H11.

| Asset | Value | per share | % | Valuation method | Value | per | % | Valuation method | Value | % change vs |
|--|-----------|-----------|-------|---|--------|---------|----------|---|--------|-------------|
| | (€ mn) | € | | | (€ mn) | share € | | | (€ mn) | OLD ADJ NAV |
| Santè SA | 139 | 0.48 | 17.9% | DCF & Market Price@ Eu11.3 | 209 | 0.71 | 23.6% | DCF (@ 8.1x 2010 EBITDA) | 135 | 3% |
| Kenan (Migros) | 247 | 0.84 | 31.8% | Mkt price (TRY 22) | 247 | 0.84 | 27.9% | Mkt price (TRY 22) | 206 | 48% |
| Kenan (Migros) cash in | 58 | 0.20 | 7.5% | Cash in from Migros placement (due 5/5/11) | 58 | 0.20 | 6.5% | Cash in from Migros placement (due 5/5/11) | | |
| FARE (ATLANTIC) SGR*** | 103.7 | 0.35 | 13.4% | 2010 MULTIPLE & NAV | 125 | 0.43 | 14.1% | 2010 MULTIPLE | 108 | -3% |
| IDeA Alternative Inv. SGR | 70.7 | 0.24 | 9.1% | 2010 MULTIPLE & NAV | 74 | 0.25 | 8.3% | 2010 MULTIPLE | 67 | 5% |
| Sigla | 11.4 | 0.04 | 1.5% | 2010 MULTIPLE & NAV | 11 | 0.04 | 1.3% | 2010 MULTIPLE | 11 | 0% |
| IDeA Funds (FOF & Colnv) | 119.8 | 0.41 | 15.4% | Fair value* | 120 | 0.41 | 13.5% | Fair value* | 120 | 0% |
| Cash, credits and marketable sec. 2008 | -24.3 | -0.08 | -3.1% | | -24 | -0.08 | -2.7% | | 15 | N.M. |
| Total ex treasury Shares | 777 | 2.65 | 100% | | 886 | 3.02 | 100% | | 662 | 17% |
| % discount | | 25% | | | | -34% | Discount | of TP vs. Fair value | | |
| Target price (Eu p.s.) | | 2.0 | | | | 2.0 | | | | |
| Current Mkt Price | | 1.50 | | | | 1.50 | | | | |
| % Upside/downside | | 32.5% | | | | -50.4% | % Upside | e/downside vs. market price | | |
| # shares (mln) net of Buy | Back Back | 293.00 | | | | | | | | |

^{*} quarterly updated by fund managers

Current price 1.50 1.50

 Discount to NAV
 -43%
 -50%

 Discount to investment value
 -43%
 -51%

Source: Intermonte SIM and Company Data

If we were to strip out our valution value of Kenan (Migros) and Santé (GDS) from current market prices, the implied value of AAM activities would be close to zero.

AAM implied valuation

459.0 Current MKt Cap

-58.0 Kenan (Migros) cash in (2Q11)

-139.4 GDS Valuation (avg with Eu 11.4 Mkt price)

-247.0 Migros Valuation (TRY 22 Mkt price)

14.6 =implied value of AAM and remaining activities

Source: Intermonte SIM

We remind that Migros Turk – which now has a 19.5% market float, has traded in the TRY22-25p.s. range, or 13.5x 2011 EV/EBITDA as of yesterday (TRY 22 p.s.). Migros Turk's main peer BIM is trading at 18x 2011 EBITDA and 29.7x P/E.

As for GDS, 2008 transactions on clinics and GDS's own clinic disposals in 2008 point to a going rate of around 12x EBITDA, while GDS's disposals of home care units and labs have fetched around 9x EBITDA. Peer group multiples currently range on average around 8.8x 2011 EBITDA. This compares with the current 6x 2011 EBITDA calculated at GDS market price and 7.4x at our valuation.

We remind that the NAV per share used in calculating our target price does not include the potential value creation from the Fare-FIMIT deal.

At current prices, DeA Capital is trading at a 44% discount to our Eu2.0 per share target price and at a 45% discount to the total value of its investments, which is Eu2.75/share.

On average, Italian holding companies trade at a 37% discount, while DeA's international peers are generally trading at a lower discount to NAV. DeA Capital's huge discount comes despite exposure to defensive businesses (50% comes from Food Retail and Healthcare) and a sound financial position.

| DEA Capital Peer group | 15/05/2011 | | | | |
|---------------------------|------------|---------|-------------|------------|--------------|
| reer group | 13/03/2011 | | | | |
| | | YTD % | Volume (EUR | P/NAV | Mkt Cap (EUR |
| | Price | change | k) | (reported) | mln) |
| Deutsche Beteiligungs | 19.58 | -2.27% | 500 | 0.98 | 282.0 |
| Dinamia | 7.72 | -12.07% | 37 | 0.72 | 92.4 |
| Eurazeo | 57.21 | 3.10% | 2380 | 0.76 | 3085.7 |
| GIMV | 44.99 | 10.08% | 487 | 1.07 | 1042.7 |
| Wendel | 81.61 | 18.43% | 14396 | 0.95 | 4106.1 |
| 3i (GBp) | 286.40 | -12.82% | 10890 | 0.87 | 1268.1 |
| Candover (GBp) | 592 | -10.98% | 198 | 0.73 | 147.4 |
| SVG Capital (GBp) | 254.40 | 20.68% | 854 | 0.81 | 429.8 |
| | | | avg. | 0.92 | |
| | | YTD % | Volume (EUR | P/NAV | Mkt Cap (EUR |
| | Price | change | ` k) | (reported) | mln) |
| DeA Capital | 1.51 | 32.34% | 162 | 0.54 | 461.7 |
| LPX Europe (-1 day) | 275.77 | 4.48% | | | |
| S&P/MIB | 21685.34 | 7.50% | | | |

Source: Bloomberg

Italian Holdings - NAV & Ratings

| Stock | Price (Eu) | Mkt cap (Eu mn) | % Change YTD as of Now | Premium (Discount) |
|---|------------|--------------------|------------------------------|-----------------------|
| EXOR S.p.A. | 24.32 | 5,658 | -1% | -31% |
| Pirelli & C. S.p.A. | 7.04 | 3,425 | 16% | -27% |
| Compagnie Industriali Riunite S.p.A. | 1.73 | 1,371 | 26% | -31% |
| Italmobiliare S.p.A. | 28.12 | 907 | 12% | -45% |
| Cofide-Compagnia Finanziaria de Benedetti S.p.A. | 0.74 | 532 | 12% | -41% |
| IMMSI S.p.A. | 0.83 | 285 | 2% | -56% |
| Camfin S.p.A. | 0.41 | 275 | 11% | -60% |
| Median Italian Holdings | | | 14% | -37% |
| Median avg. excl. see-trough NAV | | | 14% | -32% |
| Median avg. excl. see-trough NAV & at-premium NA\ | / | | 14% | -32% |

*Note: see-trough NAV for Cofide and Camfin; at-premium NAV for Premafin

Source: Intermonte SIM





1Q11 Operating Companies Results

Générale de Santé (35% of DeA Capital's pro-forma NAV) reported 1Q11 results in April that were in line with our estimates at operating level. Revenues were up 2.7% YoY (+3.3% organic) to Eu520mn and EBITDA rose 4.1% YoY to Eu78.4mn. Eu18mn of restructuring provisions brought IFRS EBIT to Eu29mn and delivered a net profit of Eu7.5mn, vs. Eu18.7mn estimated. Debt remained flat at Eu873mn. In view of this, we confirm our FY11 estimates on GDS.

Migros Turk (29% of pro-forma NAV and 39% of our valuation) reported TRY1.57bn in revenues for the year (+10% YoY); the gross margin rose 9% YoY, but EBITDA fell by 6.2% YoY due to the costs connected with repositioning the stores under the \$ok brand into a hard discount. These higher costs will probably be present in 2Q11 as well; as such, we have reduced our FY11 estimates, and going forward, as the repositioning should yield higher revenue growth, but lower margins. Net debt was up QoQ due to Eu 150mn FOREX effect.

FARE (Eu3.3bn of AuM as at YE10, 12% of pro-forma NAV) posted Eu0.7mn in net profit, below our forecast due to costs for the upcoming FARE-FIMIT merger, which is in the due diligence phase. Once this phase is concluded, we would expect a business plan to be presented after the summer for the combined entity, which will have around Eu8bn in AuM and 19 managed funds, becoming the largest independent real estate asset manager in Italy. For the time being, we confirm our standalone estimates for FARE.

IDEA AI (Eu1.6bn in AuM as at YE10, 8.4% of pro-forma NAV) posted net income of Eu0.9mn in 1Q11, vs. our Eu1.2mn estimate. We have substantially confirmed our FY 2011 estimates.

| DeA Capital | main ass | ets: Qua | rterly Res | ults and F | Y estima | tes | | | | | | | | | |
|---------------------------|-------------------|--------------------|--------------------|---------------------|---------------------|-------------------|---------------------|------------------------|----------------|-------------------|-------------------|--------------------|------------------|-------------------|--------------|
| Generale De So | antè | | | | | | | | | | | | % chang | e vs OLD | EST. |
| EU mn | 2009 A | 1Q10 A | 2Q10 A | 3Q10 A | 4Q10 A | 2,010 | 1Q11 E | 1Q11 A | A-E | 2011 E | 2012 E | 2013 E | 2011 E | | |
| Revenues | 2,046 | 506 | 498 | 425 | 497 | 1,926 | 522 | 520 | -0.5% | 1,984 | 2,052 | 2,130 | 0% | - 0% | 0% |
| YoY | 3.1% | 5.3% | -5.4% | -71.9% | -7.2% | -5.9% | 22.4% | 22.4% | | 3.0% | 3.4% | 3.8% | | | |
| Ebitda IFRS | 237 | 75 | 62 | 30 | 62 | 229 | 78 | 78 | 0.1% | 253 | 270 | 289 | 0% | 0% | 0% |
| YoY | 3.2% | 17% | 0.2% | -81.9% | -13% | -3.3% | 160% | 160% | | 10.4% | 6.5% | 7.1% | | | |
| % margin | 12% | 14.9% | 12.5% | 7.1% | 12.4% | 12% | 15.1% | 15.1% | 40.007 | 13% | 13% | 14% | 007 | 007 | 007 |
| Ebit IFRS YoY | 131 -18.1% | 76 124% | 30 -12.6% | -4 -104.8% | 70 21% | 131 -0.3% | 48 -64% | 29 -64% | -40.0% | 103 -21.3% | 150 45.0% | 169 12.7% | 0% | 0% | 0% |
| % margin | -10.1% | 15.1% | 6.0% | -0.8% | 14.1% | 7% | 5.6% | 5.6% | | 5% | 7% | 8% | | | |
| Net Income | 42 | 46 | 13 | -15 | -10 | 35 | 19 | 9 | -51.3% | 25 | 50 | 61 | 0% | 0% | 0% |
| YoY | -51.4% | 311% | 15.0% | -185.8% | -140% | -17.5% | -80% | -80% | | -29.2% | 102.0% | 22.0% | | | |
| NFP | -885 | -837 | -885 | -933 | -871 | -871 | -823 | -872 | 6% | -893 | -872 | -856 | 0% | 0% | 0% |
| Source: Compo | any Data a | nd Interm | onte SIM e | stimates | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| MICDOS TUDY | | | | | | | | | | | | | 07 ahana | O I D | ГСТ |
| MIGROS TURK YTL mn | 2009 E | 1Q10 A | 2Q10 A | 3Q10 A | 4Q10 A | 2010 | 1011 F | 1Q11 A | A-E | 2011 E | 2012 E | 2013 E | % chang 2011E | 2012E | |
| 11211111 | 2007 L | IQIOA | 2010 A | OGIOA | 4Q10 A | 2010 | IGITE | IGIIA | /\ L | 2011 2 | 2012 L | 2010 L | 2011 | ZOTZL | 2010 L |
| Revenues | 5,711 | 1,434 | 1,538 | 1,790 | 1,603 | 6,365 | 1,592 | 1,575 | -1.1% | 6,977 | 7,928 | 8,677 | 0% | 2% | 5% |
| YoY | 13% | 12% | 10% | 14% | 10% | 11% | 11% | 10% | | 10% | 14% | 9% | | | |
| Costs | -5,314 | -1353.0 | -1460.8 | -1692.7 | -1501.5 | -6,008 | -1499.4 | -1,499 | 0.0% | -6,593 | -7,452 | -8,113 | | | |
| YoY Ebitda IFRS | 397 | 14% 81.0 | 12% 77.1 | 15% 97.4 | 10% 101.5 | 13% 357 | 11% 92.3 | 11% 76.0 | -17.7% | 10% 384 | 13% 476 | 9% 564 | -8% | -10% | -9% |
| YOY | 5.6% | -16% | -19% | -9% | 4% | -10.1% | 14% | -6% | -1/.//0 | 7.5% | 24.0% | 18.6% | -0% | -10% | -9% |
| % margin | 7.0% | 5.6% | 5.0% | 5.3% | 6.3% | 5.6% | 5.8% | 5% | | 5.5% | 6.0% | 6.5% | | | |
| D&A | -132 | -30.0 | -34.8 | -31.7 | -42.4 | -139 | -34.0 | -46.9 | 38.1% | -140 | -155 | -155 | | | |
| YoY | 65.0% | -14% | | -67% | 18% | 5.3% | 13% | 1 | | 0.5% | 10.7% | 0.0% | | | |
| Ebit | 265 | 51.0 | 42.3 | 65.7 | 59.0 | 218 | 58.3 | 29.1 | -50.2% | 244 | 321 | 409 | -13% | -14% | -12% |
| YoY | -10% | -18% | -44% | -1% | -5% | -18% | 14% | -43% | | 12% | 32% | 28% | | | |
| % margin | 5% | | 3% | 4% | 4% | 3% | 4% | 2% | 00100 | 3% | 4% | 5% | | | |
| Financial Char | | 22.2 | 50.5 | -102.2 | -44.0 | -74 | -45.0 | -150.4 | 234.2% | -199 -9 | -168 | -72 | | | |
| Tax Net income | -27 110 | -14.2 59 | -19.0 74 | 6.9 -30 | -4.1 -60 | -30 43 | -2.7 11 | -10.1 -134.4 | 279.0% n.m. | -9 36 | -31 122 | -67 270 | -43% | -26% | -14% |
| YoY | -58.0% | -5% | 30% | 35% | -00 | -60.9% | -82% | -328% | 11.111. | -15.4% | 235.6% | 121.1% | -40/0 | -20/0 | -14/0 |
| NFP | 1,307 | 1,367 | 1,170 | 1,530 | 1,583 | 1,583 | 1,590 | 1,590 | | 1,571 | 1,414 | 1,121 | 15% | 21% | 36% |
| Source: Compo | nny Data | onconcur | and Intarn | aanta CIAA | astimatos | | | | | | | | | | |
| source. Compo | illy Dala, C | .oriserisos | una imem | IOI II E SIIVI E | estitiui es | | | | | | | | | | |
| | | | | New Struc | ture, net o | f IA/Wise | | | | | | | | | |
| IDEA ALTERNAT | | 1010 4 | 2010 4 | 2010 A | 4010.4* | 2010 | 1011 5 | 1011 4 | ۸. ٦ | 2011 E | 2012 5 | 2012 5 | % change | e vs OLD 2012E | |
| EU mn AUM | 2009A 2174 | 2214 | 2Q10 A 2227 | 2209 | 4Q10 A* 1447 | 2010 1447 | 1Q11 E 1447 | 1Q11 A 1501 | A-E | 1528 | 2012 E 1808 | 2013 E 1868 | 2011E 0% | 2012E 0% | 2013 E 0% |
| YoY | 21% | 1336 | | 2207 | 1447 | -33% | 1447 | | | 6% | 18% | 3% | 0,0 | 070 | 070 |
| Commissions | 11.40 | 2.7 | 2.7 | 9.3 | 4.5 | 19.20 | 4.6 | 3.8 | -17.4% | 17.59 | 18.93 | 20.67 | -10% | -8% | -9% |
| YoY | 39% | 29% | -18% | 210% | 50% | 13% | -15% | -30% | | 36% | 8% | 47% | | | |
| of which IDEA | 11.4 | 2.7 | 2.7 | 4.6 | 2.90 | 12.9 | 2.7 | 2.8 | 17.4% | 13.0 | 14.1 | 16.3 | | | |
| YoY of which OTHER | 39% | 29% | -18% - | 210% 4.70 | -3% 1. 60 | 13% 6.3 | -15% 1.90 | -30% 1. 00 | -34.8% | 14% 4.6 | 23% 4.9 | 503% 4.4 | | | |
| YOY | • | | - | 4.70 | 1.00 | n.m. | 1.70 | 1.00 | -34.0/0 | -27% | 4.7 5% | -10% | | | |
| | | | | | | | | | | 2170 | | 10,0 | | | |
| (IA, Wise, | 10.5 | 4.3 | | | | 0.0 | | | | 0.0 | 0.0 | 0.0 | | | |
| other) | 12.5 | 4.3 | n.a. | n.a. | n.a. | 0.0 | - | - | | 0.0 | 0.0 | 0.0 | | | |
| YoY | 136% | | | | | -50% | | | | -27% | 5% | -10% | | | |
| Netincome | 12.4 | 1.6 | 0.6 | 3.8 | 0.1 | 4.8 | 1.2 | 0.9 | -25.0% | 5.0 | 5.7 | 6.6 | 0% | 0% | 36% |
| *IA and WISE of | 33% | 7% | -67% | -27% | -98% | -61% | -45% | -59% | | 3% | 14% | 17% | | | |
| Source: Compo | | | | stimates | | | | | | | | | | | |



PEER GROUP valuation

Peer group Générale de Santè Minibase in EUR as of 13/05/11

| | | | Mkt Cap | Е | V/EBITDA | | | PE | |
|-----------------------------------|-------------------------|-------|---------|-------|---------------|-------|-------|-------|-------|
| Company | Crcy | Price | (Eu mn) | 2010 | 2011 | 2012 | 2010 | 2011 | 2012 |
| Generale De Sante (INTERMONTE) | EUR - Euro | 11.4 | 644 | 6.5x | 5.9x | 5.4x | 17.4x | 15.7x | 12.7x |
| Generale De Sante (consensus) | EUR - Euro | 11.4 | 644 | 6.4x | 6.1x | 5.6x | 18.4x | 15.2x | 12.5x |
| Curanum AG | EUR - Euro | 2.6 | 102 | 9.9x | 9.2x | 8.4x | | 17.0x | 14.7x |
| Orpea S.A. | EUR - Euro | 33.7 | 1,424 | 16.8x | 14.0x | 11.9x | 21.8x | 18.3x | 14.7x |
| Rhoen-Klinikum AG | EUR - Euro | 16.9 | 2,332 | 9.3x | 8.7x | 7.9x | 16.7x | 14.8x | 13.2x |
| Netcare Ltd. | ZAR - South African Rar | 1.4 | 2,053 | 8.3x | 8.8x | 8.1x | 13.3x | 12.6x | 10.6x |
| Athens Medical Centre S.A. | EUR - Euro | 0.4 | 36 | | 13.8x | 8.0x | | | |
| MediClin AG | EUR - Euro | 4.2 | 200 | 9.0x | 8.3x | 7.7x | 18.2x | 16.4x | 14.5x |
| Marseille-Kliniken AG | EUR - Euro | 2.6 | 38 | 4.4x | 7.5x | 5.3x | 96.1x | 24.4x | 10.0x |
| IASO S.A. | EUR - Euro | 1.2 | 76 | 8.5x | 11.7x | 11.1x | 14.6x | | 19.5x |
| Euromedica S.A. | EUR - Euro | 0.5 | 21 | | 8.8x | | | 15.7x | |
| Medi-Clinic Corp. Ltd. | ZAR - South African Rar | 3.0 | 1,925 | 9.6x | 8.6x | 7.6x | 15.6x | 14.3x | 11.8x |
| Medica S.A. | EUR - Euro | 15.2 | 725 | 10.9x | 9.8x | 8.5x | 26.3x | 16.6x | 13.9x |
| Source: JCF Consensus | | | | | | | | | |
| Total | | | 9,599 | | | | | | |
| Average | | | | 8.4x | 8.8x | 7.5x | 23.6x | 15.6x | 13.3x |
| Median | | | | 8.8x | 8.7x | 7.9x | 17.4x | 15.7x | 13.0x |
| Generale De Sante @ TP (INTERMONT | E) EUR - Euro | 18.8x | 1,028 | 8.2x | 7. 4 x | 6.9x | 17.4x | 15.7x | 12.7x |

Source: JCF Consensus



MIGROS TURK Peer group

Minibase in EUR as of 13/05/11

| | | Price | Mkt Cap | ΕV | / EBITDA | | | P / E | |
|-------------------------------------|-------------------|--------|----------|--------|----------|--------|---------|--------|--------|
| Company | Crcy | l.c. | Eu mn | 2010 | 2011 | 2012 | 2010 | 2011 | 2012 |
| Company | Cicy | 1.6. | EO IIIII | 2010_ | 2011 | 2012 | 2010 | 2011 | 2012 |
| Koninklijke Ahold N.V. | EUR - Euro | 9.61 | 11,458 | 5.9x | 5.6x | 5.2x | 12.8x | 10.8x | 9.7x |
| Carrefour S.A. | EUR - Euro | 30.25 | 20,547 | 6.2x | 5.4x | 4.8x | 16.1x | 12.9x | 10.8x |
| Casino Guichard-Perrachon S.A. | EUR - Euro | 74.80 | 8,279 | 6.2x | 5.7x | 5.1x | 16.0x | 14.3x | 12.5x |
| Etablissementen Franz Colruyt N.V. | EUR - Euro | 39.65 | 6,673 | 9.3x | 9.1x | 8.4x | 17.5x | 16.2x | 14.8x |
| Delhaize Group | EUR - Euro | 57.85 | 5,875 | 4.7x | 5.0x | 4.7x | 10.2x | 10.4x | 9.8x |
| Metro AG | EUR - Euro | 46.20 | 15,052 | 5.7x | 4.8x | 4.2x | 15.3x | 12.5x | 10.5x |
| Tesco PLC | GBP - UK Pound | 3.03 | 38,411 | 8.1x | 7.2x | 6.5x | 12.4x | 11.6x | 10.5x |
| Wal-Mart Stores Inc. | USD - US Dollar | 4.19 | 139,287 | 7.0x | 6.9x | 6.4x | 12.9x | 12.6x | 11.4x |
| Costco Wholesale Corp. | USD - US Dollar | 56.76 | 25,538 | 10.1x | 10.3x | 9.3x | 26.8x | 24.6x | 21.5x |
| Jeronimo Martins SGPS S/A | EUR - Euro | 12.97 | 8,149 | 11.9x | 11.1x | 9.5x | 28.2x | 22.7x | 18.7x |
| Total | | | 279,268 | | | | | | |
| Average | | | | 7.5x | 7.1x | 6.4x | 16.8x | 14.9x | 13.0x |
| Median | | | | 6.6x | 6.3x | 5.8x | 15.6x | 12.7x | 11.1x |
| Average per CAP | | | | 239.4x | 223.5x | 197.5x | 1291.8x | 989.8x | 815.5x |
| Wal-Mart de Mexico S.A.B. de C.V. | MXN - Mexican F | 34.69 | 37,282 | 18.5x | 15.0x | 12.6x | 26.3x | 22.3x | 19.1x |
| Grupo Famsa S.A.B. de C.V. | MXN - Mexican F | 21.63 | 572 | 10.2x | 8.5x | 7.6x | 21.1x | 18.9x | 14.3x |
| X5 Retail Group N.V. | USD - US Dollar | 36.50 | 6,977 | 17.7x | 10.9x | 8.2x | 25.8x | 17.1x | 12.5x |
| Seventh Continent Russia | USD - US Dollar | 7.55 | 399 | 5.6x | 5.6x | 6.0x | 10.6x | 9.0x | 8.4x |
| Magnit | USD - US Dollar | 130.88 | 8,198 | 19.4x | 14.1x | 10.4x | 25.5x | 18.2x | 13.7x |
| Organizacion Soriana S.A.B. de C.V. | MXN - Mexican F | 37.16 | 4,022 | 10.7x | 8.9x | 7.7x | 20.4x | 17.8x | 15.6x |
| Total | | | 256,664 | | | | | | |
| Average | | | | 13.7x | 10.5x | 8.7x | 21.6x | 17.2x | 13.9x |
| Median | | | | 14.2x | 9.9x | 7.9x | 23.3x | 18.0x | 14.0x |
| Migros Ticaret A.S. | TRY - New Turkish | 22.15 | 1,745 | 16.7x | 13.5x | 13.5x | n.s. | n.s. | n.s. |
| BIM Birlesik Magazalar A.S. | TRY - New Turkish | 52.25 | 3,508 | 21.7x | 18.1x | 14.8x | 29.7x | 28.2x | 23.4x |
| Average | | | | 19.2x | 15.8x | 14.1x | 29.7x | 28.2x | 23.4x |
| Median | | | | 19.2x | 15.8x | 14.1x | 29.7x | 28.2x | 23.4x |

Source: Intermonte SIM estimates, JCF consensus



ALTERNATIVE AM PEERS IDEA AI & FARE Peer group

Minibase (Local Currency) as of 13/05/11

| 2.6% 7.8% 0.4% 16.9% 3.9% 3.3% 20.7% 7.8% 11.1% 18.6% | 2010 10.6x 9.1x 6.9x 10.3x 3.6x 8.0x 23.2x 4.1x 12.4x 17.0x | 9.0x 10.0x 5.6x 10.3x 2.5x 6.1x 21.4x 3.9x 7.7x 15.1x | 7.7x 9.5x 4.5x 7.8x 2.8x 4.7x 15.0x 3.6x 5.5x | 18.0x 11.7x 14.1x 15.7x 18.3x 15.4x 13.6x 8.7x 16.0x | PE 2011 13.5x 10.1x 11.1x 13.0x 14.7x 13.8x 9.7x 7.8x 14.1x | 9.1x 9.0x 10.9x 12.8x 12.1x 8.4x 6.7x 9.0x |
|---|---|--|---|--|--|---|
| 7.8% 0.4% 16.9% 3.9% 3.3% 20.7% 7.8% 11.1% | 10.6x 9.1x 6.9x 10.3x 3.6x 8.0x 23.2x 4.1x 12.4x | 9.0x 10.0x 5.6x 10.3x 2.5x 6.1x 21.4x 3.9x 7.7x | 7.7x 9.5x 4.5x 7.8x 2.8x 4.7x 15.0x 3.6x 5.5x | 18.0x 11.7x 14.1x 15.7x 18.3x 15.4x 13.6x 8.7x 16.0x | 13.5x 10.1x 11.1x 13.0x 14.7x 13.8x 9.7x 7.8x | 9.1x 9.0x 10.9x 12.8x 12.1x 8.4x 6.7x 9.0x |
| 7.8% 0.4% 16.9% 3.9% 3.3% 20.7% 7.8% 11.1% | 9.1x 6.9x 10.3x 3.6x 8.0x | 10.0x 5.6x 10.3x 2.5x 6.1x 21.4x 3.9x 7.7x | 9.5x 4.5x 7.8x 2.8x 4.7x 15.0x 3.6x 5.5x | 11.7x 14.1x 15.7x 18.3x 15.4x 13.6x 8.7x 16.0x | 10.1x 11.1x 13.0x 14.7x 13.8x | 9.1x 9.0x 10.9x 12.8x 12.1x 8.4x 6.7x 9.0x |
| 7.8% 0.4% 16.9% 3.9% 3.3% 20.7% 7.8% 11.1% | 9.1x 6.9x 10.3x 3.6x 8.0x | 10.0x 5.6x 10.3x 2.5x 6.1x 21.4x 3.9x 7.7x | 9.5x 4.5x 7.8x 2.8x 4.7x 15.0x 3.6x 5.5x | 11.7x 14.1x 15.7x 18.3x 15.4x 13.6x 8.7x 16.0x | 10.1x 11.1x 13.0x 14.7x 13.8x | 9.1x 9.0x 10.9x 12.8x 12.1x 8.4x 6.7x 9.0x |
| 0.4% 16.9% 3.9% 3.3% 20.7% 7.8% 11.1% | 6.9x 10.3x 3.6x 8.0x 23.2x 4.1x 12.4x | 5.6x 10.3x 2.5x 6.1x 21.4x 3.9x 7.7x | 4.5x 7.8x 2.8x 4.7x 15.0x 3.6x 5.5x | 14.1x 15.7x 18.3x 15.4x 13.6x 8.7x 16.0x | 11.1x 13.0x 14.7x 13.8x 9.7x 7.8x | 9.0x 10.9x 12.8x 12.1x 8.4x 6.7x 9.0x |
| 0.4% 16.9% 3.9% 3.3% 20.7% 7.8% 11.1% | 6.9x 10.3x 3.6x 8.0x 23.2x 4.1x 12.4x | 5.6x 10.3x 2.5x 6.1x 21.4x 3.9x 7.7x | 4.5x 7.8x 2.8x 4.7x 15.0x 3.6x 5.5x | 14.1x 15.7x 18.3x 15.4x 13.6x 8.7x 16.0x | 11.1x 13.0x 14.7x 13.8x 9.7x 7.8x | 9.0x 10.9x 12.8x 12.1x 8.4x 6.7x 9.0x |
| 16.9% 3.9% 3.3% 20.7% 7.8% 11.1% | 10.3x 3.6x 8.0x | 10.3x 2.5x 6.1x 21.4x 3.9x 7.7x | 7.8x 2.8x 4.7x 15.0x 3.6x 5.5x | 15.7x 18.3x 15.4x 13.6x 8.7x 16.0x | 13.0x 14.7x 13.8x 9.7x 7.8x | 10.9x 12.8x 12.1x 8.4x 6.7x 9.0x |
| 3.9% 3.3% 20.7% 7.8% 11.1% | 3.6x 8.0x 23.2x 4.1x 12.4x | 2.5x 6.1x 21.4x 3.9x 7.7x | 2.8x 4.7x 15.0x 3.6x 5.5x | 18.3x 15.4x 13.6x 8.7x 16.0x | 14.7x 13.8x 9.7x 7.8x | 12.8x 12.1x 8.4x 6.7x 9.0x |
| 20.7% 7.8% 11.1% | 8.0x 23.2x 4.1x 12.4x | 6.1x 21.4x 3.9x 7.7x | 15.0x 3.6x 5.5x | 13.6x 8.7x 16.0x | 9.7x 7.8x | 8.4x 6.7x 9.0x |
| 20.7% 7.8% 11.1% | 23.2x 4.1x 12.4x | 21.4x 3.9x 7.7x | 15.0x 3.6x 5.5x | 13.6x 8.7x 16.0x | 9.7x 7.8x | 8.4x 6.7x 9.0x |
| 7.8% 11.1% | 4.1x 12.4x | 3.9x 7.7x | 3.6x 5.5x | 8.7x 16.0x | 7.8x | 6.7x 9.0x |
| 7.8% 11.1% | 4.1x 12.4x | 3.9x 7.7x | 3.6x 5.5x | 8.7x 16.0x | 7.8x | 6.7x 9.0x |
| 7.8% 11.1% | 4.1x 12.4x | 3.9x 7.7x | 3.6x 5.5x | 8.7x 16.0x | 7.8x | 6.7x 9.0x |
| 11.1% | 12.4x | 7.7x | 5.5x | 16.0x | | 9.0x |
| | | | | | 14.1x | |
| 10,407 | 1 17 0∨ | 1 = 1 | | | | |
| | 1 | | 12.1x | 15.2x | 15.4x | 13.4x |
| 12.8% | 9.7x | 9.4x | 7.8x | 16.1x | 14.6x | 13.1x |
| 0.4% | 8.7x | 5.7x | 4.4x | 12.2x | 11.4x | 8.6x |
| 79.8% | 30.0x | 21.0x | 16.0x | 42.6x | 29.6x | 23.3x |
| 0.4% | | | | | | |
| 1.0% | | 7.8x | 4.6x | | 56.3x | 5.4x |
| | 16.1x | 11.0x | 8.2x | 23.6x | 28.0x | 12.6x |
| | 9.7x | 8.6x | 6.2x | 16.1x | 22.1x | 10.9x |
| | | | | | | |
| | | | | | | |
| | 17.0x | | | | | |
| | 6.8x | 7.9x | 6.6x | 15.4x | 15.7x | 13.8x |
| | | | | | 77.9x | 13.7x |
| 1 | 11.9x | 7.9x | 6.6x | 15.4x | 46.8x | 13.8x |
| | 11.9x | 7.9x | 6.6x | 15.4x | 46.8x | 13.8x |
| | | | | 111111 11111 | 11111 11111 11111 | 11.9x 7.9x 6.6x 15.4x 46.8x |

Source: Intermonte SIM estimates, JCF consensus



DISCLAIMER (for more details go to http://intermonte.it/ disclosures.asp)

IMPORTANT DISCLOSURES

IMPORTANT DISCLOSURES

Interproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution.

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by the Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to affer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or sell securities.

This disclaimer is constantly updated on Intermonte's website www.intermonte.it under DISCLOSURES. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question.

ANALYST CERTIFICATION

ANALYST CERTIFICATION

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities.

Intermonte's intermal procedures and codes of conduct are aimed to ensure the importation of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are more.

recommendations are made

GUIDE TO FUNDAMENTAL RESEARCH.
Reports on all companies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published. Explanation of our ratings system:

Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period;

OUTPERFORM; stock expected to outperform the market by between 10% and 25% over a 12 month period;

NEUTRAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period;

UNDEPFERFORM; stock expected to underperform the market by between -10% and -25% over a 12 month period;

SEL: stock expected to underperform the market by over 25% over a 12 month period.

The stock price indicated is the reference price on the day prior to the publication of the report.

CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS
Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms. As at Marchr 31st 2011 Intermonte's Research Department covered 126 companies

Intermonte's distribution of stock ratings is as follows:

BUY: 16.67% OUTPERFORM: 40.48% NEUTRAL: 33.91%

UNDERPERFORM: 7.94% SELL: 0.79%

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (30 in total) is as follows:

BUY: 16.67% OUTPERFORM: 33.33% NEUTRAL: 50.00% UNDERPERFORM: 0.00% SELL: 0.00%

CONFLICT OF INTEREST

- In order to disclose its possible conflicts of interest Intermonte SIM states that:

 within the last year, Intermonte SIM managed or co-managed/is managing or is co-managing (see companies indicated in bold type) an Institutional Offering of the securities of the following Companies: Enel Green Power, TBS Group;

 Intermonte SIM is Specialist and/or Corporate Broker and/or Broker in charge of the share buy back activity of the following Companies: Biancamano, B&C Speakers, Buongiorno, Carroro, Cattolica Assicurazioni, Cementir, Cogeme, Datalogic, DeA Capital, Digital Bros, Dmail, EEMS, Eurotech, Fiera Milano, Fintel Energia Group, First Capital, Gefran, IGD, IW Bank, Meridie, M&C Management e Capitali, Pierrel, QF Alpha Immobiliare, QF Beta Immobiliare, Reno de Medici, Reply, Saes Getters, Servizi Italia, TBS Group, Ternienergia, Vittoria Assicurazioni. VR Way
- Assiculazion, v. K. m.y.
 Intermonte SIM SDA and its subsidiaries do not hold a stake of equal to or over 1% in any class of common equity securities of the subject company;
- Intermonte SIM SpA acts as Financial Advisor to the following companies: Cattolica Assicurazioni

DETAILS ON STOCKS RECOMMENDATION

| Stock NAME | DEA CAPITAL | | |
|----------------------|-------------|-----------------------|------------|
| Current Recomm: | BUY | Previous Recomm: | BUY |
| Current Target (Eu): | 2.00 | Previous Target (Eu): | 1.70 |
| Current Price (Eu): | 1.51 | Previous Price (Eu): | 1.56 |
| Date of report: | 17/05/2011 | Date of last report: | 11/04/2011 |

© Copyright 2010 by Intermonte SIM - All rights reserved
It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.
INTERMONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization.
INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid.
Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product.

INTERMONTE SIM is MIRID compliant - for our Best Execution Policy please check our Website www.intermonte.it/miflid Further information is available